Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) FCF Margin (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed FCF Margin for 4 consecutive years, with 283.43% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin fell 27351.0% year-over-year to 283.43%, compared with a TTM value of 45.94% through Sep 2025, up 4798.0%, and an annual FY2024 reading of 53.48%, up 219904.0% over the prior year.
  • FCF Margin was 283.43% for Q3 2025 at Atara Biotherapeutics, down from 41.64% in the prior quarter.
  • Across five years, FCF Margin topped out at 9.93% in Q3 2024 and bottomed at 6646.91% in Q2 2023.
  • Average FCF Margin over 4 years is 1170.41%, with a median of 98.89% recorded in 2024.
  • The sharpest move saw FCF Margin tumbled -94652bps in 2023, then surged 660920bps in 2024.
  • Year by year, FCF Margin stood at 89.53% in 2022, then plummeted by -1057bps to 1036.05% in 2023, then surged by 93bps to 74.99% in 2024, then plummeted by -278bps to 283.43% in 2025.
  • Business Quant data shows FCF Margin for ATRA at 283.43% in Q3 2025, 41.64% in Q2 2025, and 28.67% in Q1 2025.